The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
Abstract Background The COVID-19 outbreak was declared a worldwide emergency as a result of its rapid spread. The number of people infected with COVID-19 is increasing rapidly around the world, and pneumonia can develop in COVID-19 cases. The monoclonal antibody tocilizumab blocks the interleukin-6...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SpringerOpen
2024-08-01
|
| סדרה: | The Egyptian Journal of Bronchology |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1186/s43168-024-00314-w |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|